Nonprescription Nexium heartburn medicine launches (Update)

by Linda A. Johnson

A nonprescription version of Nexium, the most popular medicine for frequent, severe heartburn, has just gone on sale.

Drugmaker Pfizer Inc. said Tuesday that over-the-counter Nexium 24HR is available for online orders at www.Nexium24HR.com and will be in most retailers nationwide within three days.

The nonprescription version is a 20-milligram dose of "the purple pill," known chemically as esomeprazole.

Patients are to take one pill daily for up to 14 days, so it's sold in packages of 14, 28 or 42 pills, priced at about $15 to $30. Prescription Nexium, which will still be available in 20- and 40-milligram strengths, costs $260 a month or more, without insurance coverage.

New York-based Pfizer said it's planning consumer ads about the launch, which it's begun promoting at www.facebook.com/Nexium24HR . Pfizer also is offering $1-off coupons for it on the website and www.coupons.com .

In 2012, Pfizer acquired exclusive worldwide rights to nonprescription Nexium from maker AstraZeneca PLC. The British drugmaker got a payment of $250 million and will receive royalties and other payments based on the level of sales.

AstraZeneca will manufacture the nonprescription version for Pfizer and continue selling prescription Nexium, which can take one to four days for full effect. It's heavily advertised as "the purple pill that can provide 24-hour relief from persistent heartburn" caused by acid reflux disease. Unlike antacids, Nexium blocks the "pumps" that release acid into the stomach.

The Food and Drug Administration approved over-the-counter Nexium 24HR two months ago.

Last year, Nexium was the sixth-best-selling prescription drug in the world, generating revenue of $7.86 billion, up 7 percent from 2012 sales, according to health data firm IMS Health. Competition from the nonprescription version likely will reduce sales in the future.

Over the past month, Pfizer repeatedly courted AstraZeneca, offering as much as $119 billion to buy the company in what would have been the biggest pharmaceutical acquisition ever. After repeated rebuffs, Pfizer ended its pursuit Monday.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Canadian study OKs Losec and Nexium

Feb 27, 2008

Health Canada has completed a review of safety information for Losec (omeprazole) and Nexium (esomeprazole) and found no increased cardiovascular risks.

Pfizer, Teva reach deal to allow generic Viagra

Dec 17, 2013

Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

FDA says heartburn drugs can interfere with Plavix

Nov 17, 2009

(AP) -- Federal health officials said Tuesday a popular variety of heartburn medications can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack ...

AstraZeneca fends off Pfizer with new growth plan

May 06, 2014

AstraZeneca on Tuesday outlined plans to make sales jump over the next decade, an effort to persuade shareholders the drug maker can do well as an independent company, rather than get bought out by rival ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments